参考文献 References
[1] 张一琼, 于江燕, 朱元方, 等. 子宫内膜癌肿瘤微环境的研究进展[J]. 现代肿瘤医学, 2016, 24(16): 2651-2655.
[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and MortalityWorldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[3] C Kirchhoff, I Habben, R lvell, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors[J]. Biology of Reproduction, 1991, 45(2): 350-7.
[4] 赵灵琴, 陈曦, 陈鲁, 等. 人附睾分泌蛋白4和CA125联合检测在子宫内膜恶性肿瘤与子宫良性肿瘤鉴别诊断中的价值[J]. 中国癌症杂志, 2012, 22(11): 5.
[5] Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients[J]. British Journal Cancer, 2011, 104(9): 1418-1425.
[6] Li J, Wang X, Qu W, et al. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis[J]. Clinica Chimica Acta, 2019, 488: 215-220.
[7] Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up[J]. International Journal of Gynecologic Cancer, 2016, 26(1): 2–30.
[8] Kalogera E, Scholler N, Powless C, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer[J]. Gynecologic Oncology, 2012, 124(2): 270-275.
[9] Brennan D J, Hackethal A, Metcalf A M, et al. Serum HE4 as a prognostic marker in endometrial cancer—a population based study[J]. Gynecologic Oncology, 2014, 132(1): 159-165.
[10] 陈燕娥, 吴学明, 温云花. 子宫内膜癌患者血清HE4, CA125及 CA19-9 的表达及与临床病理特征的关系[J]. 中国老年学杂志, 2017, 37(015): 3787-3789.
[11] Espiau Romera A, Cuesta Guardiola T, Benito Vielba M, et al. HE 4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer[J]. International Journal of Gynecology & obstetrics, 2020, 149(3): 265-268.
[12] Brennan D J, Hackethal A, Mann K P, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance[J]. Bmc Cancer, 2015, 15(1): 33.
[13] Abbink K, Zusterzeel P L, Geurts-Moespot A J, et al. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients[J]. Tumour Biology the Journal of the International Society for Oncodevelopmental Biology & Medicine, 2018, 40(2): 1010428318757103.
[14] 刘光泉, 黄可, 胡凯, 等. D-dimer和HE4联合检测在子宫内膜癌诊断中的应用[J]. 南京医科大学学报(自然科学版), 2020, 40(12): 1852-1854.
[15] 陈毅红, 杨汉才, 罗强, 等. 血清HE4, CA125联合血浆D-二聚体检测在子宫内膜癌诊断中的应用价值[J]. 中国卫生标准管理, 2023, 14(19): 46-49.
[16] 兰新志. 血清HE4, CA125和血浆D-二聚体在子宫内膜癌的表达及联合检测的临床价值[J]. 实验与检验医学, 2019, 37(5): 916-918.